10:01 AM EST - NetraMarkHoldings Inc. : Announced new findings illustrating the ability of its proprietary explainable AI platform, NetraAI, to uncover clinically meaningful responder subgroups within the landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial. NetraMarkHoldings Inc.
shares T.AIAI are trading unchanged at $1.00.
